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Abstract
Background: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging epidemic infectious disease
with high mortality in East Aisa, especially in China. To predict the prognosis of SFTS precisely is important in
clinical practice.
Methods: From May 2013 to November 2015, 233 suspected SFTS patients were tested for SFTS virus using RT-PCR.
Cox regression model was utilized to comfirm independent risk factors for mortality. A risk score model for mortality
was constructed based on regression coefficient of risk factors. Log-rank test was used to evaluate the significance of
this model.
Results: One hundred seventy-four patients were confirmed with SFTS, of which 40 patients died (23%). Baseline age,
serum aspartate aminotransferase (AST) and serum creatinine (sCr) level were independent risk factors of mortality. The
area under ROC curve (AUCs) of these parameters for predicting death were 0.771, 0.797 and 0.764, respectively. And
hazard ratio (HR) were 1.128, 1.002 and 1.013, respectively. The cutoff value of the risk model was 10. AUC of the model
for predicting mortality was 0.892, with sensitivity and specificity of 82.5 and 86.6%, respectively. Log-rank test indicated
strong statistical significance (×2 = 88.35, p < 0.001).
Conclusions: This risk score model may be helpful to predicting the prognosis of SFTS patients.
Keywords: Risk model, Severe fever with thrombocytopenia syndrome, Prediction, Mortality
Background
Severe fever with thrombocytopenia syndrome (SFTS) is
an emerging epidemic infectious disease in China, Korea
and Japan caused by a novel bunyavirus, SFTS virus
(SFTSV). It has become an important public health
threat in Asia, especially in China. The national surveil-
lance data from 2010 to 2013 in China showed that the
incidence of SFTS and its epidemic areas are growing,
but the case fatality rate (CFR) has steadily declined [1].
The major clinical symptoms of SFTS include fever,
thrombocytopenia, leukocytopenia, gastrointestinal symp-
toms and various other systemic manifestations including
muscular symptoms, neurological disorders and coagu-
lopathy [2, 3]. Neurological symptoms were strongly as-
sociated with death, even though they occurred during
the first week after disease onset [4]. Other factors
associated with death include viral load [5–8], advanced
age, serum aspartate aminotransferase (AST), lactate
dehydrogenase (LDH) and creatine kinase (CK) levels,
and decreased lymphocyte percentages [7–12].
We and others [13] have found in clinical practice that
though some patients had similar symptoms at admis-
sion, including altered consciousness and multiple organ
dysfunctions and received similar therapy, their clinical
courses were quite different. However, several patients
who died afterwards did not exhibit neurological disor-
ders at admission. Thus it is important to predict the
prognosis of the patients in clinical practice.
Though the viral load is a predictor of morbidity [13],
in contrast to routine laboratory examination, which is
quickly and easily performed, the level of SFTS viral
RNA requires several days to determine, and can only be
conducted at a limited number of local disease control
institutes. Furthermore, the viral RNA only becomes de-
tectable in most cases at three days and reaches maxi-
mum level at six days after disease onset. In 55.6% of the
patients, viral RNA was undetectable at hospital
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admission [8]. In this study, we established a risk score
model for predicting mortality of SFTS patients based on
their clinical and demographic characteristics, and routine
laboratory tests including biochemical, hematological pa-
rameters and coagulation variables.
Methods
Clinical samples and laboratory testing
Patients with clinical manifestations of suspected SFTS,
including fever (body temperature >38.0 °C prior to
admission or at admission), thrombocytopenia, leukocy-
topenia and gastrointestinal symptoms were tested for
SFTSV via reverse transcription–polymerase chain reac-
tion (RT–PCR) using total RNA extracted from a peri-
pheral blood sample [14] at local institute for disease
preventation and control. The results are given as positive
or negative afterwards for clinicians to confirm SFTSV
infection. Clinical history and manifestation, physical
examination, routine biochemical, hematological and co-
agulation results at enrollment were retrospectively col-
lected from confirmed SFTS patients. Hematological
parameters were detected using an XT1800I blood cell
analyzer and biochemical parameters using a CI16200
blood biochemical automatic analyzer. Neurological
symptoms included: limb shaking, lower jaw shaking,
dysarthria and discordance of consciousness.
Parameters which entered in Cox univariate regression
analysis included: age, gender, body temperature, time in-
tervals between symptom onset to admission, hema-
tological parameters, biochemical parameters, coagulation
indicators and neurological symptom.
This study was conducted according to the Helsinki II
Declaration and approved by the ethics committee at the
National Institute of Parasitic Diseases, Chinese Center
for Disease Control and Prevention. Written informed
consent was obtained from the patients.
Statistical analysis
Statistical analyses were performed using the SPSS,
version 16.0, software (IBM, Armonk, NY, USA). Mann–
Whitney U test was used for variables with an abnormal
distribution between the survival and death groups. Cox
univariate and multivariate regression analysis was ap-
plied to determine the risk factors among parameters at
admission that were associated with mortality of SFTS
patients. Factors with p < 0. 1 in univariate analysis were
included in Cox multivariate regression analysis. Risk
score model was established based on the acquired re-
gression coefficients of the determined risk factors to
predict mortality. Criterion for factors that include in
the regression model was that the factors present in the
last step of forward conditional with p < 0.05 and Hazard
ratios (HR) >1.0. Receiver-operating characteristic (ROC)
curves and area under the curve (AUC) were constructed
to assess the predictive power of the model. Patients were
divided into high-risk and low-risk groups according to
cutoff values obtained from ROC analysis. The Kaplan-
Meier survival analysis was used to compare the cumula-
tive risk for death in the two groups, and the significance
of difference was tested with the log-rank test. ×2 test was
utilized to compare mortality rate between patients with
above and less than cutoff value of risk model. p < 0.05
was considered to be statistically significant.
Results
Demographic and clinical characteristics of SFTS patients
Among the 233 suspected cases with fever, throm-
bocytopenia, fatigue and diarrhea admitted to our hospital
from May 2013 to November 2015, 174 were finally diag-
nosed as SFTS by detecting SFTSV using RT-PCR. Forty
patients (23%) subsequently died. The survival group
included 63 women (47.0%) and 71 men (53.0%), while the
non-survival group comprised of 19 women (47.5%) and
21 men (52.5%). Gender composition was identical in the
two groups. The median age was 64 (range 28–84) years,
and was significantly higher among those who died (range
52–84 years; p < 0.001).
The major baseline clinical symptoms and findings in-
cluded fever (n = 102, 58.6%), fatigue (n = 120, 69.0%),
loss of appetite (n = 86, 50%) diarrhea (n = 12, 6.9%),
superficial lymphadenopathy (n = 72, 41.4%), neutropenia
(n = 110, 63.2%), thrombocytopenia (n = 174, 100%) and
neurological symptoms (n = 63, 36.2%). Among those who
survived, 38 cases manifested neurological symptoms.
Nine cases had severe neurological symptoms included
abnormal level of consciousness. Others exhibited mainly
limb shaking. Among those patients who have died, 25
cases had neurological symptoms (60%) at admission and
other developed central neurological symptoms primarily
discordance of consciousness and coma within 3–7 days.
Ages of those with severe neurological symptoms who
survived are younger than those who died (62.3 ± 7.8 vs.
70.9 ± 9.5, p < 0.05).
Body temperature at admission in surviving and fatal
cases (37.4 ± 0.98°Cvs 37.5 ± 1.1 °C, p >0.05) were com-
parable. The time intervals between symptom onset to
admission were also similar between the two groups
(6.5 ± 3.3 vs 5.6 ± 1.9, p >0.05). Hospitalization duration
was longer in patients who recovered than those who
died (13.0 ± 5.5 vs 3.4 ± 2.4, p < 0.001).
Comparison of biochemical and hematological
parameters in surviving and fatal SFTS cases
For the biochemical parameters, levels of alanine amino-
transferase (ALT), AST, total bilirubin (TB), high-sensitivity
C-reactive protein (hs-CRP), blood urea nitrogen (BUN),
serum creatinine (sCr), troponin (Ctnl), CK, hydroxy-
butyrate dehydrogenase (HBDH), LDH, prothrombin
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time (PT) and international normalized ratio (INR)
were dramatically increased in the fatal cases. While
the prothrombin time activity percentage (PTA) was
markedly decreased. Concentrations of serum potas-
sium (K+) and phosphorus (P3+) in the fatal cases were
significantly elevated, whereas sodium (Na+), calcium
(Ca2+) and hydrocarbonate (HCO3-) were notably
reduced.
For the hematological parameters, white cell blood
(WBC) count, neutrophil (NEU) count, neutrophil/
lymphocyte (N/L) ratio, mean corpuscular volume
(MCV) and red blood volume distributing width
(RDW) in the fatal cases were remarkably increased.
Red blood cell (RBC) count, lymphocyte (LYM) count,
PLT count and thrombocytocrit (PCT) were promin-
ently decreased. These results are shown in Tables 1
and 2.
Establishment of risk score model
Cox regression model analysis showed that baseline pa-
rameters, including age, serum AST level and sCr level
were independent risk factors of mortality. HR (95% CI),
and mean survival times of these factors are shown in
Table 3. Age is the most remarkable risk factor among
these parameters with HR = 1.128.
The cutoff values and area under ROC curve (AUCs)
of these parameters for predicting death are included in
Table 4. AST level has the highest predictive value
among these factors. Based on regression coefficients of
multivariate Cox regression analysis of these factors, we
constructed a risk score model for the prediction of
mortality in SFTS patients.
Model Mð Þ ¼ 0:002  AST þ 0:121  AGE 
þ 0:013  sCr
The cutoff value of the score model was 10. Patients
with >10 were at high-risk of mortality. AUC of the
model for predicting mortality was 0.892, with sensitivity
and specificity of 82.5 and 86.6%, respectively. Mean sur-
vival time of patients with M > 10 is shorter than those
with M ≤ 10. Log-rank test indicated strong statistical
significance (×2 = 88.35, p < 0.001). Data are shown in
Tables 3 and 4. ROCs and survival curves are depicted
in Figs. 1 and 2. Of those with M ≤ 10 (n = 123), 7 cases
died (5.7%). And of those with M > 10 (n = 51), 33 cases
Table 1 Comparison of biochemical parameters in survivals and
non-survivals of STFS patients (x ±SD)
Parameters Survival Non-survival p
N 134 40
Male/female 71/63 21/19 >0.05
Age (year) 61.2 ± 9.9 71 ± 9.5 <0.001
Hospital stays (day) 13.0 ± 5.5 3.4 ± 2.4 <0.001
Body temperature (°C) 37.4 ± 0.98 37.5 ± 1.0 >0.05
ALT (U/L) 95.4 ± 86.7 191.8 ± 148.8 <0.001
AST (U/L) 210.3 ± 219.0 713.4 ± 572.9 <0.001
TB (μmol/L) 11.6 ± 5.0 19.0 ± 13.4 <0.001
HCO3-(mmol/L) 24.1 ± 3.0 22.6 ± 5.5 <0.05
Ca2+ (mmol/L) 1.96 ± 0.13 1.86 ± 0.17 <0.01
P3 + (mmol/L) 0.93 ± 0.25 1.04 ± 0.31 <0.05
Hs-CRP (mg/L) 9.6 ± 11.6 18.3 ± 15.7 <0.001
Dimer (ng/L) 5.2 ± 10.5 14.4 ± 22.4 <0.001
BUN (mmol/L) 4.9 ± 2.4 10.1 ± 5.9 <0.001
SCr (μmol/L) 64.1 ± 16.3 115.1 ± 79.3 <0.001
UA (μmol/L) 286.8 ± 117.6 430.4 ± 192.2 <0.001
Ctnl (ng/mL) 8.5 ± 93.6 1.2 ± 3.6 <0.001
CK (U/L) 916.7 ± 1424.4 2372.0 ± 3680.1 <0.001
CK-MB (U/L) 47.8 ± 54.8 85.5 ± 78.5 <0.001
HBDH (U/L) 4846.8 ± 326.2 967.1 ± 848.2 <0.001
LDH (U/L) 804.1 ± 811.8 1989.3 ± 1862.1 <0.001
PT (s) 12.2 ± 1.3 13.6 ± 2.0 <0.01
PTA (%) 107.1 ± 18.9 89.1 ± 17.3 <0.01
INR 0.98 ± 0.11 1.09 ± 0.17 <0.01
ALT alanine aminotransferase, AST aspartate aminotransferase, hs-CRP high-
sensitivity C-reactive protein, BUN blood urea nitrogen, sCr serum creatinine,
Ctnl troponin, CK creatine kinase, HBDH hydroxybutyrate dehydrogenase, LDH
lactate dehydrogenase, PT prothrombin time, PTA prothrombin time activity
percentage, INR international normalized ratio
Table 2 Comparison of hematological parameters in survivals
and non-survivals of STFS patients (x ±SD)
Parameters Survival Death p
WBC (×109/mL) 4.02 ± 2.71 4.14 ± 2.68 >0.05
NEU (%) 58.3 ± 17.1 68.5 ± 16.7 <0.01
LYM (%) 30.2 ± 13.4 21.6 ± 11.0 <0.01
N/L ratio 2.77 ± 2.50 4.74 ± 3.77 <0.01
MON (%) 10.78 ± 6.62 8.47 ± 6.36 <0.05
EOS (%) 0.08 ± 1.07 1.25 ± 1.73 >0.05
RBC (×1012/mL) 4.6 ± 0.53 4.39 ± 0.45 <0.05
Hb (g/L) 138.7 ± 18.1 138.5 ± 14.7 >0.05
HCT (%) 39.1 ± 4.5 38.6 ± 4.3 >0.05
MCV (fL) 85.0 ± 5.6 88.0 ± 6.4 <0.01
RDW (%) 13.3 ± 1.3 14.5 ± 7.9 <0.05
PLT (×109/mL) 60.8 ± 35.6 40.2 ± 13.7 <0.01
PCT 0.07 ± 0.04 0.05 ± 0.03 <0.01
MPV (fL) 11.0 ± 1.0 10.8 ± 2.1 >0.05
WBC white blood cell, NEU neutrophil, LYM lymphocyte, N/L ratio neutrophil/
lymphocyte ratio, MON monocyte, EOS eosnophils, RBC red blood cell,
Hb hemoglobin, HCT hematocrit, MCV mean corpuscular volume, RDW red
cell distribution width, PLT platelet count, PCT thrombocytocrit, MPV mean
platelet volume
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died (64.7%). Mortality rates between two groups had
strong significant difference (×2 = 70.9, p < 0.001).
Prospective validation
The cutoff value of M (=10) was prospectively validated
in a cohort of SFTS patients (n = 67) enrolled in our
hospital this year. Of whom, 51 cases survived (76.1%)
and 16 died (23.9%). Of those patients with M ≤ 10
(n = 39, 58.2%), 36 cases survived (92.4%) and 3 cases
died (7.6%). Of those with M > 10 (n = 28, 41.8%), 13
cases died (46.4%) and 15 cases survived (53.6%).
Mortality rates between these two groups had signifi-
cant difference (×2 = 13.5, p < 0.001).
Discussion
In this study, we established a risk model for the predic-
tion of mortality of SFTS patients that showed relatively
high predictive value with high sensitivity and specificity.
The model contains 3 high-risk factors including age,
serum AST level and sCr level, which have moderate
predictive values for mortality when used independently.
Numerous observational studies have shown that neuro-
logical symptoms were strongly associated with death.
In this study, though not all the fatal patients have
neurological symptoms at admission, all cases developed
neurological symptoms afterwards. While, results showed
that neurological symptoms was not an independent risk
factor. The reason may be that neurological symptoms in
survival patients were relative mild and the symptoms
were severe in the death group. Ages of those critical pa-
tients with severe neurological symptoms who survived
were younger than those who died. As we shown, age is
the highest risk factor of the parameters. Elevated serum
AST and sCr level may represent multi-organ dysfunction.
Other factors such as time intervals between symptom
onset and treatment initiation, and therapeutic methods
may also influence the prognosis of the patients. A de-
layed diagnosis of SFTS could affect the prognosis of the
patients [4].
Other study showed that cytokines, such as interleu-
kine (IL)-1, IL-6, IL-10, granulocyte colony stimulating
factor (G-CSF), interferon inducible protein-10 (IP-10)
and monocyte chemoattractant protein (MCP-1) were
profoundly elevated in fatal cases, and their levels corre-
lated with various clinical parameters [10]. While, the
measurements of several serum cytokine levels together
are too expensive to be performed by all healthcare facil-
ities in China, so it is unsuitable to be used to predict
the clinical prognosis.
Though only 58.6% patients had fever at adimissiom,
and body temperature was not associated with progno-
sis, all patients had fever prior admission or body
Table 3 Hazard ratio (HR) and means survival time of factors independently associated with mortality
Parameters HR (95% CI) Cutoff value Mean time (days) (95%CI) Log Rank
×2 p
Age (year) 1.128 (1.071,1.189) ≤66 28.8 ± 0.86 (27.2, 30.6) 28.3 <0.001
>66 17.9 ± 1.72 (14.5, 21.2)
AST (U/L) 1.002 (1.001,1.003) ≤437 28.6 ± 0.8 (27.0, 30.0) 55.1 <0.001
>437 11.2 ± 1.76 (7.7, 14.6)
sCr (μmmol/L) 1.013 (1.006,1.020) <70 23.7 ± 0.66 (22.4, 25) 35.7 <0.001
≥70 17.4 ± 1.96 (13.5, 21.2)
M ≤10 30.3 ± 0.62 (29.1, 31.5) 88.4 <0.001
>10 12.0 ± 1.83 (8.4, 15.6)
Table 4 Cut-off values, AUCs of age and biochemical parameters for the prediction of mortality of SFTS patients with sensitivity and
specificity
Parameters cutoff value AUCs (95%CI) SEN (%) SPE (%) PPV (%) NPV (%) LR+ LR-
Age (year) 66 0.771 (0.701, 0.831) 75 70.2 42.9 90.4 2.51 0.36
AST (U/L) 437 0.797 (0.730, 0.854) 60 90.3 64.9 88.3 6.18 0.44
sCr (μmml/L) 70 0.764 (0.692, 0.827) 71.8 77.6 50.0 89.8 3.21 0.36
M 10 0.892 (0.829,0.955) 82.5 86.6 64.7 94.3 6.14 0.20
AUC area under, ROC curve, SEN sensitivity, SPE specificity, PPV positive predictive value, NPV negative predictive value, LR+ positive likelihood ratio, LR- negative
likelihood ratio
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temperature elevated after admission. Fever and fatigue
were the main chief complaint of SFTS patients. Though
the fatality rate of SFTS in China has fallen from first re-
ported 30% to present 12% owing to increased reporting,
advances in diagnostic procedures and improved clini-
cians’ skills [5, 15, 16]. The risk factors for human infec-
tion with SFTSV were confirmed [15, 17] and national
intervention programs were performed, including pro-
moting public awareness, establishing sentinel hospitals
and improving clinicians’ skills [2, 18–20]. Yet, the num-
ber of fatal cases increases annually in China.
Except for new treatment methods tried in a few
therapies with few patients in Japan and South Korea
[21–23], supportive care remains the standard treat-
ment for SFTS. Therefore, accurate prediction of the
prognosis may help clinicians to perform intervention
measures in advance, control the disease progression
and improve the prognosis.
In the prospective study, we showed that the model is
more suitable for the prediction of survival than for
mortality. The model we constructed will be helpful for
the prediction of SFTS prognosis. And the results will be
further prospectively validated by a more larger cohort
of patients.
This study had several limitations. Firstly, we had no
quantitative results of the virus RNA and only had the
positive results. Secondly, patients with subclinical or
minor infection signs who sought medical care were
perhaps not tested for SFTSV. Thirdly, some patients
with mild manifestations may have been excluded due
to their low/undetectable viral loads. All these factors
influence the accuracy of registered incidence and
mortality.
Conclusions
In summary, the risk score model that we established is
useful for predicting death in patients with SFTS and
may be applicable in clinical practice.
Fig. 1 ROC curve and area under ROC curve of risk score model for
the prediction of mortality of SFTS patients
Fig. 2 Survival curve of SFTS patients based on risk score model
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